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bstract
Kaposi’s sarcoma-associated herpesvirus (KSHV) is associated with Kaposi’s sarcoma and primary effusion lymphoma (PEL). The KSHV
eplication and transcription activator (RTA) and latency-associated nuclear antigen (LANA) play key roles in activating KSHV lytic replication and
aintaining KSHV latency, respectively. Phosphorodiamidate morpholino oligomers (PMO) are similar to short single-stranded DNA oligomers,
ut possess a modified backbone that confers highly specific binding and resistance to nucleases. In this study, RTA and LANA mRNA in PEL
ells were targeted by antisense peptide-conjugated PMO (P-PMO) in an effort to suppress KSHV replication. Highly efficient P-PMO uptake by
EL cells was observed. Treatment of PEL cells with a RTA P-PMO (RP1) reduced RTA expression in a dose-dependent and sequence-specific
anner, and also caused a significant decrease in several KSHV early and late gene products, including vIL-6, vIRF-1, and ORF-K8.1A. KSHViral DNA levels were reduced both in cells and culture supernatants of RP1 P-PMO-treated cells, indicating that KSHV lytic replication was
uppressed. Treatment of BCBL-1 cells with P-PMO against LANA resulted in a reduction of LANA expression. Cell viability assays detected no
ytotoxicity from P-PMO alone, within the concentration range used for the experiments in this study. These results suggest that RP1 P-PMO can
pecifically block KSHV replication, and further study is warranted.
2006 Elsevier B.V.
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. Introduction
Nucleic acid-based strategies used to block gene expression
nclude RNA decoys and antisense compounds. RNA decoys are
ligoribonucleotides that compete for a translational activator
r mRNA-stabilizing elements, and cause translation inhibition
r mRNA destruction (Beelman and Parker, 1995; Liebhaber,
997). Antisense strategies employ various structural types of
NA- or DNA-based oligomers, ribozymes or DNAzymes, and
mall-interfering RNAs (siRNA). All of these approaches are
ased on Watson-Crick base-pairing of antisense agent to com-
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Open access under CC BY-NC-ND license.lementary sequence in the mRNA selected for targeting. To
e useful in vivo these strategies will likely need to utilize
odified nucleic acid backbone structures to provide protec-
ion from host nucleases. Additionally, a candidate therapeutic
ust be able to effectively enter cells of relevant tissues and
ccess target RNA. PMO are structurally similar to single-
tranded DNA oligonucleotides, but have a different backbone;
morpholine ring replaces the deoxyribose sugar, and a phos-
horodiamidate linkage replaces the phosphodiester linkage of
NA (Fig. 1) (Schmajuk et al., 1999; Summerton, 1999). PMOs
re uncharged, water-soluble, highly resistant to nuclease degra-
ation (Hudziak et al., 2000), and are typically synthesized to
e approximately 20 bases in length. PMO can bind to target
RNA and prevent translation initiation by steric blockade,
hich is distinct from the RNase H-dependent mechanism of
ction induced by antisense structural types based on DNA
hemistry (Summerton, 1999). Additionally, PMO conjugated to
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Fig. 1. Structure of P4-PMO and locations of P-PMO targets in KSHV immediately early (IE) and latent transcripts. (A) The deoxyribose and phosphodiester bond
of the DNA backbone are replaced by a morpholine ring and a phosphorodiamidate linkage, respectively, in PMO. “B” represents the bases A, G, C, or T. The
peptide R5F2R4, designated P4, when present, was covalently conjugated to the 5′ end of PMO. (B) Positions of P-PMO designed against KSHV RTA and LANA
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2ranscripts. The arrows and the numbers in bold font above arrows indicate open
n the KSHV genomic sequence (Russo et al., 1996). The sizes of the latent tra
t al., 1998) and latent transcripts (Dittmer et al., 1998; Talbot et al., 1999) are
mall, positively charged peptides have far greater delivery effi-
iency to cells in culture than non-conjugated PMO (Moulton et
l., 2003, 2004).
The sequence-specific antiviral efficacy of PMO compounds
n cell culture has been documented with caliciviruses (Stein
t al., 2001), Hepatitis C virus RNA (McCaffrey et al., 2003),
ouse hepatitis virus (Neuman et al., 2004), SARS coronavirus
Neuman et al., 2005), Equine arteritis virus (van den Born et al.,
005) and several flaviviruses (Deas et al., 2005; Kinney et al.,
005). PMOs have been extensively used to study gene function
n zebrafish developmental embryology, a model with relevance
o the study of human diseases (Corey and Abrams, 2001;
asevicius and Ekker, 2000; Penberthy et al., 2002; Scholpp
nd Brand, 2001). To our knowledge, the application of PMO-
echnology against a DNA virus has not yet been reported. In this
tudy, a morpholino antisense approach was utilized to reduce
he production of replication and transcription activator (RTA)
s well as latency-associated nuclear antigen (LANA) proteins
f Kaposi’s sarcoma-associated herpesvirus (KSHV).
KSHV is a large DNA virus associated with Kaposi’s sar-
oma (KS), a type of skin tumor recognized as the most common
alignancy among patients with AIDS. KSHV is also associated
ith several lymphoproliferative disorders, including primary
ffusion lymphoma (PEL) and multicentric Castleman’s disease
MCD) (Cesarman et al., 1995a; Chang et al., 1994; Soulier et
l., 1995). Like other herpesviruses, KSHV causes two modes of
nfection: latent and lytic. In latency, the KSHV genome persists
ith limited gene expression in host cells (Fakhari and Dittmer,
002; Sarid et al., 1998). LANA, encoded by ORF73, has a
ajor role in the maintenance of KSHV latency (Ballestas et al.,
999; Lan et al., 2004; Lim et al., 2002, 2004; Shinohara et al.,
002). LANA interacts with p53 and represses its transcriptional
ctivity (Friborg et al., 1999), targets retinoblastoma-E2F tran-
criptional regulatory pathway, and transforms primary rat cells
n cooperation with the oncogene Hras (Radkov et al., 2000).
ANA also up-regulates the telomerase promoter (Verma et al.,
004) and modulates host cellular gene expression (An et al.,
2
(ng frames. The numbers above the transcript lines indicate nucleotide positions
ts are indicated above each line. The predicted splicing events of both IE (Sun
atically illustrated.
005; Renne et al., 2001). Mutagenic disruption of ORF73 can
ead to abortive KSHV episome persistence (Ye et al., 2004).
hen KSHV latency is disrupted the virus switches to a lytic
hase in which infectious virions are produced, and then spread
rom cell to cell. The lytic reactivation of virus replication in PEL
ells can be induced by various chemicals, such as the phorbol
ster tetradecanoyl phorbol acetate (TPA) and sodium butyrate
Renne et al., 1996). KSHV lytic replication can be divided into
mmediate-early, early and late stages. A key immediate-early
ene, ORF50 encodes RTA, and this protein activates viral lytic
ene expression (Sun et al., 1998).
RTA activates downstream viral genes of both early and late
inetic classes, including many cellular homologues and non-
tructural genes, such as vIRF-1, homologues of macrophage
nflammatory protein I and II, vIL-6, vCyclin, viral G-protein-
oupled receptor (GPCR), and a homologue of Bcl-2 (Moore
t al., 1996). Proinflammatory cytokines are considered to be
ssential for the development of KSHV-associated malignancies
Ensoli et al., 1991; Moore et al., 1996). In KSHV-infected PEL
ells and in KS lesions, a low percentage (<5%) of cells main-
ain KSHV lytic replication (Miller et al., 1997). Lytic cycle
ctivation is a pivotal event in the cascade of events involved
ith KSHV replication. RTA is essential as a controlling fac-
or of viral replication during the lytic phase, and contributes
o the development of KSHV-associated diseases. In this report,
e demonstrate highly efficient uptake of P-PMO by KSHV-
nfected BCBL-1 cells, as well as highly effective sequence-
pecific inhibition of RTA and LANA protein expression. Viral
enes characteristically expressed downstream of RTA were also
uppressed as a result of specific P-PMO-mediated inhibition.
. Materials and methods.1. Cells and viruses
KSHV-infected cells BC-1 (EBV-positive) and BCBL-1
EBV-negative) were derived from body cavity-based lym-
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homas (Cesarman et al., 1995b; Renne et al., 1996). BJAB
s a KSHV- and EBV-negative lymphoma cell line (Menezes et
l., 1975). All cell lines were maintained in RPMI 1640 medium
upplemented with 10% fetal bovine serum. Cell numbers were
ounted using a hemocytometer and cell viability was assessed
y trypan blue exclusion. For induction of KSHV lytic replica-
ion, TPA (Sigma, St Louis, MO) was added to the cell growth
edium to a final concentration of 20 ng/mL.
.2. PMO and P-PMO design and synthesis
PMO were synthesized and purified at AVI BioPharma Inc.
Corvallis, OR) as previously described (Summerton and Weller,
997) and were designed to be complementary to specific KSHV
NA sequences. PMO were covalently conjugated at the 5′
nd to a peptide, NH2-RRRRRFFRRRRC-CONH2, designated
5F2R4 (Fig. 1). The methods of conjugation, purification, and
nalysis of R5F2R4-PMO (P4-PMO, hereafter referred to as P-
MO) were similar to those described previously (Moulton et
l., 2004). All PMO-compounds used in this study and their tar-
et sites in KSHV, are summarized in Table 1 and depicted in
ig. 1. Fluorescein was conjugated to the 3′ end of a control
MO sequence in both non-conjugated (PMO-Fl) and peptide-
onjugated (P-PMO-Fl) forms (see Table 1), for assessing PMO
ptake by BCBL-1 cells.
.3. Plasmid construction and cell-free luciferase reporter
ssay
Complementary oligonucleotides of ORF50 sequence from
ases −22 to +14 relative to the AUG translation initiation codon
ere synthesized and cloned into a luciferase reporter vector
n a manner similar to that described previously (Neuman et
l., 2004). The inserted ‘leader’ sequence included the RP1 P-
MO target region, and was cloned upstream of AUG-ablated
uciferase sequence in the reporter vector. DNA sequencing
as conducted to confirm that the insert sequence was in-
rame with the luciferase open reading frame. The plasmid DNA
as linearized downstream of the target-luciferase fusion gene
nd in vitro transcription was conducted with MegaScript Kit
2
l
able 1
-PMOa sequences and target sites
-PMOa name P-PMO sequence (5′–3′)
P1b GTCATCTTGCGCCATTTTTGTGG
RP1d GTCAACTTCCGCGATTATTGTCG
P1 GCCATCCTCGGGAAATCTGG
P2 GACGTGACTGCTTCGTGGCGCA
P3 GCGGGCGCTACTCACTGTTTAT
-PMO-F1f AGTCTCGACTTGCTACCTCA
MO-F1f AGTCTCGACTTGCTACCTCA
P1 GATATACACAACACCCAATT
a The peptide R5F2R4 (designated ‘P4’) is conjugated to the 5′ end of all PMO exc
b The underlined nucleotides correspond to the AUG translation initiation codon of
c GenBank accession number for the cDNA of RTA (ORF50) mRNA is AF091350
d The underlined nucleotides indicate those changed in comparison to the RP1 sequ
e GenBank accession number for the KSHV genome sequence is U75698. The num
f P-PMO-F1 and PMO-F1 were conjugated to carboxy-fluorescein at 3′ end of thesearch 73 (2007) 12–23
Ambion, Austin, TX). Cell-free translation reactions were per-
ormed with the Rabbit Reticulocyte Lysate System (Promega,
adison, WI). Different concentrations of RP1 P-PMO were
dded to translation reactions in order to determine its ability
o inhibit luciferase production. LP1, which has no sequence
omology with RP1, was included in the assay as a control.
uciferase activity in the cell-free translation reactions was
easured using an FLx800 microplate luminometer (Bio-Tek
nstruments Inc., Winooski, VT). The relative light units pro-
uced by each reaction were normalized to the mean of all con-
rol reactions and expressed as percent inhibition of luciferase
ranslation.
.4. PMO/P-PMO uptake analysis
BCBL-1 cells were counted, pelleted and resuspended in
PMI 1640 medium supplemented with 100g/mL bovine
erum albumin (BSA). The cells were transferred to 12-well
ell culture plates at 106 cells per well immediately before PMO
ompound application. BCBL-1 cells were incubated in 8M
MO-F1 or P-PMO-F1 at 37 ◦C with gentle shaking for 4 h, after
hich the cells were pelleted, washed with phosphate-buffered
aline (PBS, pH 7.2) to remove free PMO-compound, and then
bserved under a fluorescence microscope.
For flow cytometry analysis, the PMO/P-PMO-treated
CBL-1 cells were pelleted, fixed with 1% paraformaldehyde in
BS for 15 min at room temperature, and analyzed in the FAC-
Calibur system using CellQuest software program version 3.3
BD Biosciences, San Jose, CA). Green fluorescence was mea-
ured using a 525 nm band pass filter.
To test whether P-PMO could stably persist in BCBL-1 cells,
he cells were cultured in growth medium (RPMI 1640 supple-
ented with 10% fetal bovine serum), treated with P-PMO-F1
s described above, and harvested at 24, 48 or 72 h for analysis
y fluorescence microscopy and flow cytometry..5. P-PMO treatment of KSHV-infected cells
KSHV-infected BC-1 and BCBL-1 cells were counted, pel-
eted and resuspended in RPMI 1640 medium supplemented
P-PMO target site (nucleotide positions)
ORF50 translation initiation region (76–98)c
ORF50 translation initiation region (76–98)
ORF73 translation initiation region (127293–127312)e
5′UTR of LANA latent transcript (127852–127873)
Splice donor site in 5′UTR of LANA latent transcript (127799–127820)
Random control sequence
Random control sequence
Random control sequence
ept PMO-Fl.
RTA mRNA.
.
ence.
bers in parentheses indicate nucleotide positions in the genome.
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ith 100g/mL BSA. The cells were transferred to a 12-well
ell culture plate, at 106 cells per well, immediately before P-
MO treatment. P-PMO were diluted in culture media and added
o the cells. Control P-PMO CP1 was included as a negative con-
rol. Cells treated with PBS were included as a mock-treatment
ontrol. After mixing, the cells were incubated for 4 h at 37 ◦C.
rowth medium supplemented with TPA, at 20 ng/mL, was then
dded to a final volume of 1.5 mL per well. The cells were incu-
ated for 48 h at 37 ◦C. Cells and culture supernatants were
arvested for further analysis. For time-kinetic analysis, TPA
as added to the cells at 0, 0.5, 1, 2, 3, or 4 h after the com-
encement of P-PMO treatment. Growth medium was added to
he cells 4 h after P-PMO treatment.
For LANA P-PMO treatment, the same protocol was fol-
owed, but TPA was omitted from the growth medium. Recurrent
pplications of the LANA P-PMO, at 2-day intervals to BCBL-1
ells, were also tested, as described above.
.6. Immunoﬂuorescence assay (IFA)
IFA was utilized to detect proteins in cells as described pre-
iously (Gao et al., 1996). Briefly, cells were pelleted, rinsed
n PBS three times, and spotted onto slides. The slides were
eat-fixed for 2 h at 56 ◦C. Polyclonal rabbit anti-RTA anti-
ody was used to detect RTA expression (Wang et al., 2003).
ouse monoclonal antibody against vIRF-1 (a gift from Dr.
eiji Ueda of Osaka University School of Medicine, Japan),
ouse monoclonal antibody against a glycoprotein encoded by
SHV ORF-K8.1A, rat anti-LANA monoclonal antibody and
olyclonal rabbit anti-vIL-6 antibody (Advanced Biotechnolo-
ies Inc., Columbia, MD) were used to detect vIRF-1, K8.1A,
ANA, and vIL-6 proteins in the cells, respectively. Goat anti-
ouse IgG-fluorescein isothiocynate (FITC), anti-rat IgG-FITC,
r anti-rabbit IgG-FITC (Sigma) conjugates were used to iden-
ify specific reactions. Stained cells were observed under fluo-
escence microscopy.
For flow cytometry analysis, cells were fixed in 1%
araformaldehyde and permeabilized with 0.1% Triton X-100
n PBS for 5 min at room temperature. The rabbit anti-RTA anti-
ody and goat anti-rabbit IgG-FITC conjugates were used to
etect RTA protein. The stained cells were resuspended in PBS
nd analyzed in the FACSCalibur system (BD Biosciences) as
escribed above. Cells were mock-stained or stained with sec-
ndary antibody only when included as negative controls.
.7. Western blot analysis
RTA protein expression in KSHV-infected cells was iden-
ified by Western blot analysis. BCBL-1 cells were lysed and
esolved in 12% polyacrylamide gels by SDS-PAGE. The sep-
rated proteins were transferred to nitrocellulose membrane
nd probed with rabbit anti-RTA antiserum. Any specific reac-
ion was detected with goat anti-rabbit IgG conjugated with
orseradish peroxidase (Sigma) and the addition of chemilumi-
escence substrate. Chemiluminiscence signal was collected by
VersaDoc 3000 digital imaging system (Bio-Rad Laboratories,
ercules, CA). Tubulin was detected on the same blot mem-
i
a
o
ssearch 73 (2007) 12–23 15
ranes to normalize protein loading in the analysis. Similarly,
rotein expression from vIRF-1, vIL-6, K8.1A and LANA gene
roducts was detected with the respective antibodies described
bove. Digital image analyses were conducted using Quantity
ne software (Version 4.4) (Bio-Rad).
.8. Cell viability assay
The effect of P-PMO treatment on BCBL-1 cell viability
as determined with CellTiter-Blue (Promega). Briefly, BCBL-
cells were treated with RP1 or CP1 under identical conditions
o those described in section 2.5 above, in the absence of virus.
ock-treated cells were included for comparison. BCBL-1 cells
ithout TPA induction were also included as a control. CellTiter-
lue reagent was added and incubated for 1 h at 37 ◦C. The
uorescence signal was measured with a Synergy HT Multi-
etection Microplate Reader (Bio-Tek).
.9. Statistical analysis
A single factor ANOVA statistical analysis was conducted to
est target protein expression differences between the groups of
MO-treated cells (Strum and Kirk, 1988). A two-tailed P-value
f less than 0.05 was considered significant.
.10. DNA isolation and real-time PCR
Genomic DNA from cell culture supernatants was isolated
sing DNAzol (Invitrogen, Carlsbad, CA) and DNA from
ells was isolated with Wizard Genomic DNA Purification
it (Promega). Real-time PCR was conducted with a Chromo
Detector system (Bio-Rad) using a primer set (73-RF2, 5′
GACT TCGCC AACCG TAG 3′ and 73-RR2, 5′ CCTAT
GAGA TGGGA GATGT AG 3′) that was expected to amplify
equence in the ORF73 gene, and iQ SYBR Green Super-
ix (Bio-Rad). A recombinant plasmid pcDNA3.1/His-ORF73
Rainbow et al., 1997) was quantified and used to generate stan-
ard curves for the real-time PCR. Cellular -actin DNA was
lso amplified in order to assure normalized quantitative PCR
etection of KSHV DNA from cells.
. Results
.1. Design of P-PMOs against KSHV RTA and LANA
ranscripts
RP1 P-PMO was designed to base pair with the ORF50/RTA
mmediate early transcript at translational initiation codon
egion (Fig. 1). A control P-PMO, with five-base changes to
he RP1 sequence, was also synthesized (mRP1, see Table 1) to
elp evaluate if RP1-mediated inhibition of RTA expression was
ndeed sequence-specific. Three P-PMO were designed to target
RF73/LANA. LP1 is complementary to the LANA translationnitiation region (Fig. 1). LP2 and LP3 P-PMO were designed
gainst separate sequences in the 5′ untranslated region (UTR)
f a latent LANA transcript (Fig. 1). LP3 targets a splice donor
ite (Dittmer et al., 1998; Talbot et al., 1999).
16 Y.-J. Zhang et al. / Antiviral Re
Fig. 2. PMO/P-PMO uptake assay in KSHV-infected BCBL-1 cells. BCBL-1
cells were treated for 4 h with 8M concentration P-PMO-F1 and photographed
under fluorescent microscopy (A). Flow cytometry analysis of BCBL-1 cells
treated with P-PMO-Fl or PMO-F1 was conducted (B). BCBL-1 cells were
treated with P-PMO-Fl for 4 h and harvested for flow cytometry analysis at
4 (Pink), 24 (Black), 48 (Red) and 72 (Green) h after PMO application. The
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as expected. In untreated cells after TPA induction, approxi-
mately 20% of BCBL-1 cells expressed RTA, as detected by
IFA (Fig. 4A). In induced cells, treatment with RP1 resulted in
reduction of cells signaling positive for RTA to approximately
Fig. 3. Cell-free luciferase reporter assay. P-PMO was added to in vitro transla-
tion reactions containing RNA transcribed from a reporter construct that includedcale on the X-axis represents fluorescence intensity and the scale on Y-axis is
requency count. Note the P-PMO uptake and stable presence in BCBL-1 cells
t all four time points.
.2. Cellular uptake of P-PMO by BCBL-1 cells
PMO are neutral in charge, and their conjugation to arginine-
ich peptide assists delivery into a variety of cells (Moulton et al.,
003, 2004); however, there is no literature concerning uptake
f PMO compounds by B lymphocytes. In order to investigate
his issue, BCBL-1 cells were incubated with PMO-Fl or P-
MO-F1 at a final concentration in the media of 8M. After
h incubation, microscopy revealed that virtually all of the cells
reated with P-PMO-F1 exhibited green fluorescence (Fig. 2A),
hile no fluorescence was observed in cells treated with PMO-
1. The results indicate highly efficient uptake of P-PMO-F1,
nd poor uptake of PMO-Fl, by BCBL-1 cells under these culture
onditions.
Flow cytometry analysis was conducted to quantify the
egree of cellular uptake. A high percentage of BCBL-1
ells treated with P-PMO-F1 for 4 h were fluorescence-positive
Fig. 2B), while cells treated with PMO-F1 were fluorescence-
egative.
To evaluate persistence of P-PMO-F1 after uptake, BCBL-1
ells were treated with P-PMO-F1 for 4 h, rinsed, replenished
ith media, and harvested 24, 48 and 72 h later for analysis
y fluorescence microscopy and flow cytometry. Green fluo-
escence was still observed in almost all cells at all three time
R
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p
tsearch 73 (2007) 12–23
oints. Flow cytometry analysis likewise showed that over 95%
f the cells had green fluorescence at all three time points
Fig. 2B). BCBL-1 cells treated with PBS were included as a
ock-treatment control, and no fluorescence was observed in
hese cells at any time point. Green fluorescence in the P-PMO-
1 treated cells was still observed at day 7 after treatment, but
howed reduced intensity (data not shown). The reduction in
uorescence intensity may have been due to cell division and/or
ignal quenching.
.3. RP1 inhibition of target RNA translation in a cell-free
uciferase reporter assay
Characterization of RP1 P-PMO mediated inhibition of trans-
ation was carried out with the use of a rabbit reticulocyte lysate
ell-free translation assay system. Binding of RP1 P-PMO to its
arget in in vitro transcribed RNA was expected to reduce trans-
ation of the downstream luciferase reporter. Luciferase activity
as reduced by RP1 treatment in a dose-responsive manner,
ith 98% inhibition at 300 nM RP1, in comparison to a mock-
reatment control. Identical treatment with LP1 did not have any
ffect, indicating a sequence-specific mechanism caused the RP1
ediated inhibition (Fig. 3).
.4. P-PMO dose-dependent inhibitory effect on RTA
rotein expression
To investigate the ability of RP1 P-PMO to interfere with
ranslation in living cells, we applied it at a concentration of
6M to BCBL-1 cells, and determined the effect on RTA pro-
ein expression. In untreated, non-induced BCBL-1 cells, less
han 1% of cells were RTA-positive, which indicates that a
mall number of cells have spontaneous KSHV lytic replication,P1 P-PMO target sequence upstream of, and in-frame with, firefly luciferase
oding sequence. LP1 P-PMO was included as a negative control. Luciferase
ctivity in the presence of RP1 or CP1 P-PMO is compared, and graphed as the
ercentage of mock-treated reactions, which was set as 100%. The average of
hree tests is shown and the error bar represents variation among the experiments.
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Fig. 4. RP1 P-PMO inhibition of RTA protein expression in BCBL-1 cells post TPA induction. (A) Immunofluorescence assay with anti-RTA antibody. Cells were
treated with RP1 or CP1 P-PMO (16M) as described in text. The cell nuclei were counterstained blue by 4′,6′-diamidino-2-phenylindole (DAPI) in mounting
solution (Molecular Probes). The lower image panel was taken from the same observed fields as the upper panel, but with a DAPI filter to reveal all cells. Note the
reduction in RTA-positive cells in the RP1-treated sample (TPA + RP1) in comparison to CP1-treated (TPA + CP1) or mock-treated (TPA + No PMO). (B) Western
blot analysis showing dose-responsive inhibition of RTA expression. The same blot was incubated with an anti-tubulin antibody as a protein loading control. RTA
signal after TPA induction in BCBL-1 cells was reduced with increasing RP1 concentration, while CP1 did not cause a detectable change. Mock-treated cells were
included in the experiment for comparison. (C) Quantitative image analysis confirmed the dose-responsive inhibition of RTA expression by RP1. RTA expression in
cells treated with P-PMO is shown as a relative percentage to that of the mock-treated control. (D) Flow cytometry analysis. The number of RTA-positive cells after
P-PMO treatment is shown as a percentage of the total cells counted. The average of three tests is shown and the error bar represents variation among experiments.
The cells treated with RP1 had a significantly lower number of RTA-positive cells (P < 0.001) in comparison to cells CP1- or mock-treated. (E) Treatment of BCBL-1
cells with a 5 base-change mutant form of RP1 (mRP1) yielded no detectable change in RTA expression by Western blot analysis. This experiment was repeated
three times and had similar results; a representative experiment is shown.
1 ral Re
5
t
e
B
f
1
p
e
i
R
t
d
t
T
b
e
r
t
i
Q
o
9
f
i
m
c
w
w
y
T
7
t
m
h
w
t
1
e
T
t
I
e
P
u
e
o
3
i
e
T
v
F
v
n
P8 Y.-J. Zhang et al. / Antivi
%, compared with approximately 20% of mock-treated or con-
rol P-PMO CP1-treated cells (Fig. 4A).
The inhibitory effect of RP1 on RTA expression was further
xamined in KSHV-infected BC-1 cells co-infected with EBV.
C-1 cells were treated in the same manner as described above
or BCBL-1 cells. IFA results found that in TPA-induced BC-
cells, RP1 treatment markedly reduced the number of RTA-
ositive cells compared to mock-treated cells, while CP1 had no
ffect (data not shown).
In an effort to confirm the IFA observation of RP1-mediated
nhibition, Western blot analysis was performed to determine
TA protein levels in the cells after TPA induction and P-PMO
reatment. BCBL-1 cells were treated with a series of two-fold
ilutions of RP1 or CP1, ranging from 0.125 to 16M. Cells
reated with PBS were included as a mock treatment control.
otal-cell lysates were subjected to SDS-PAGE and Western
lot analysis. The blots show that the level of RTA protein
xpression in TPA-induced BCBL-1 cells was reduced in a dose-
esponsive manner by RP1 P-PMO (Fig. 4B), while identical
reatment with CP1 P-PMO resulted in no detectable change
n RTA expression (Fig. 4B), confirming the IFA observation.
uantitative digital image analysis revealed that RP1 treatment
f TPA-induced BCBL-1 cells inhibited RTA expression up to
1% when compared to mock-treatment (Fig. 4C). These results
urther demonstrate that RP1 inhibited RTA protein expression
n BCBL-1 cells in a dose-dependent and sequence-specific
anner.Flow cytometry was also conducted, and the results further
onfirmed the above IFA and Western blot data. BCBL-1 cells
ere treated with RP1 or CP1 at a concentration of 8M. RTA
as detected with rabbit anti-RTA antibody. Similar to IFA anal-
a
y
i
d
ig. 5. Western blot analysis to evaluate inhibition of expression of KSHV lytic gen
IRF-1, and a glycoprotein encoded by ORF-K8.1A in TPA-induced BCBL-1 cells
ot cause a detectable change (B). Quantitative image analysis confirms the dose-re
-PMO in comparison to mock-treated cells.search 73 (2007) 12–23
sis, less than 1% of non-induced, and approximately 25% of
PA-induced BCBL-1 cells, were RTA-positive. Approximately
% of induced cells treated with RP1 were RTA-positive, and
his number was significantly lower than that in CP1-treated or
ock-treated cells (P < 0.001) (Fig. 4D). Cells treated with CP1
ad the same profile as the mock treatment control.
It has been shown that ORF50/RTA transcription is induced
ithin 4 h of the addition of TPA, and that KSHV early lytic gene
ranscripts are detectable 8–13 h after TPA induction (Sun et al.,
999). Our results show that RP1 P-PMO can inhibit RTA protein
xpression when TPA is added 4 h post RP1 P-PMO application.
o characterize the kinetics of RP1 activity, TPA was added
o cells at 0, 0.5, 1, 2, 3 or 4 h after RP1 P-PMO application.
FA analysis showed that RP1 treatment reduced RTA protein
xpression at all of these time points (data not shown). A P-
MO with five base-changes in RP1 sequence (mRP1), tested
nder identical conditions as RP1, had no effect on RTA protein
xpression (Fig. 4E), confirming the sequence-specific activity
f RP1.
.5. Effect of RP1 on KSHV lytic replication
Because RTA is an immediate-early gene that plays a key role
n activating KSHV lytic replication, inhibition of RTA protein
xpression may be expected to block KSHV lytic replication.
o investigate this possibility, expression of KSHV lytic genes
IL-6, vIRF-1 and a glycoprotein encoded by ORF-K8.1A, were
nalyzed in RP1-treated BCBL-1 cells by Western blot anal-
sis. In comparison to mock-treated BCBL-1 cells after TPA
nduction, expression of these lytic genes was decreased in a
ose-dependent manner after treatment with RP1 (Fig. 5A); up
es downstream from RP1, in RP1-treated BCBL-1 cells. Expression of vIL-6,
was reduced with increasing RP1 P-PMO concentration (A). CP1 P-PMO did
sponsive inhibition of vIL-6 (C) and vIRF-1 (D) in the cells treated with RP1
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pig. 6. Real-time PCR to assess KSHV viral DNA level in cells (A) and cultu
illiliter. The P-PMO RP1 and mRP1 were used at a concentration of 16M.
escribed in Section 2.10.
o 98% for vIL-6 (Fig. 5C) and 93% for vIRF-1 (Fig. 5D). In
ontrast, the levels of these proteins in cells treated with CP1 did
ot have any detectable change (Fig. 5B). These results indicate
hat inhibition of RTA expression by RP1 resulted in a reduction
f KSHV lytic replication.
LANA is a latent gene product that is expressed constitutively
n KSHV-infected cells. To determine the effect of RP1 treatment
n KSHV latency, Western blot analysis was conducted to detect
ANA levels in BCBL-1 cells treated with RP1. No detectable
hange in signal generated with a LANA antibody was found in
P1-treated cells, in comparison to mock-treated or CP1-treated
ells (data not shown).
We also assessed KSHV replication in PEL cells post 16M
P1 or mRP1 treatment. Real-time PCR was conducted with
ntracellular and cell culture supernatant samples, in order to
easure viral DNA levels. It is established that addition of TPA
o cell culture media leads to the induction of KSHV lytic repli-
ation (Renne et al., 1996). In this experiment TPA induction
ncreased the KSHV viral DNA level by 1.84- and 2.75-fold in
ells and culture supernatant, respectively (Fig. 6). Cells treated
ith mRP1 had viral DNA levels similar to the background
evel observed in mock-treated samples. The KSHV viral DNA
evel post mRP1 treatment was 2.6- and 2.2-fold as high as that
ost RP1 treatment. This result further demonstrates that RP1
reatment can specifically result in inhibition of KSHV lytic
eplication.
.6. Cell viability assay of BCBL-1 cells after RP1
reatment
Cell viability assays were conducted with P-PMO, in order
o assess cytotoxicity, and exclude the possibility that reduction
f target gene expression in test cells was being misinterpreted.
CBL-1 cells were treated with either RP1 or CP1, at concen-
rations of 8 and 16M, under conditions identical to the above
xperiments. The cell densities used in the assay were within
he linear range of this method of detection by fluorescent inten-
ity. BCBL-1 cells without P-PMO treatment were included as
mock treatment control. Relative percentages of fluorescence
ntensity were calculated in comparison to the mock-treatment
ontrol. The assay was repeated three times and the averages of
he percentages were: 103 and 96% for cells treated with 8 and
4
ppernatants (B). Viral DNA in samples is shown as copies in log 10 value per
bars show variations of three experiments. Real-time PCR was performed as
6M RP1, 106 and 107% for cells treated with 8 and 16M
P1, and 103% for the non-induced control. These results show
hat RP1 and CP1 had no detectable cytotoxicity under the con-
itions used in the experiments in this report.
.7. The suppression of LANA by P-PMO treatment
Three P-PMO designed to target LANA were evaluated in
CBL-1 cells. Application of LP1 at 8M concentration to
CBL-1 cells had no effect on LANA expression according to
FA and Western blot analysis. Because LANA is constitutively
xpressed by BCBL-1 cells at high levels, recurrent application
f LP1 every 2 days, for a total of 6 days, was tested, but no
hange in LANA level was detected. To obtain confirmation
hat the LP1 P-PMO was capable of binding to its target RNA,
cell-free reporter assay with LP1/luciferase RNA, similar to
he RP1/luciferase system described above, was conducted. LP1
as found to be effective at inhibiting translation in this reporter
ystem (data not shown). These results suggest that either LP1
as unable to access KSHV target RNA in BCBL-1 cells, or
hat successful hybridization of LP1 and its target RNA had lit-
le biological impact.
Application of LP2 and LP3 at 1 and 8M concentrations,
o BCBL-1 cells, caused reduction in LANA protein level as
etected by IFA and Western blot (Fig. 7). IFA showed that
hree repeated P-PMO treatments to the same BCBL-1 cells,
ver 2-day intervals, reduced LANA protein expression, while
he same recurrent applications of CP1 or mock treatment had
o detectable effect (Fig. 7A). LANA protein levels were also
valuated by Western blot analysis. LANA protein expression
as significantly reduced after a three-time treatment with 8M
P2 or LP3 (Fig. 7B), but remained stable in the mock treatment
ontrol. Treated with LP2 or LP3 generated over 60% reduction
n LANA protein level after the second application and up to 92%
eduction after the third application (Fig. 7C). LP2 appeared to
e somewhat more potent than LP3 in the suppression of LANA
rotein expression in this experiment.. Discussion
Our study demonstrates that P-PMO can specifically sup-
ress protein expression of KSHV RTA and LANA. RTA is a
20 Y.-J. Zhang et al. / Antiviral Research 73 (2007) 12–23
Fig. 7. Inhibition of LANA expression in BCBL-1 cells. Immunofluorescence assay with anti-LANA antibodies shows LP2 or LP3 inhibits LANA protein expression
in BCBL-1 cells (A). BCBL-1 cells were treated with 8M LP2, LP3, or CP1 three times at 2 days intervals, as described in text. The cell nuclei were counterstained
to blue by DAPI in mounting solution (Molecular Probes). The lower image panel was taken with a DAPI filter from the same fields as the upper panel. Note that
LANA-staining is much weaker in cells treated with LP2 or LP3 than in cells treated with CP1 P-PMO, or mock-treatment. Total LANA protein expression was also
evaluated by Western blot analysis (B). Total proteins from all three treatments were collected separately and used for Western blot. The number above each lane
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tepresents the number of P-PMO applications, at 2-day intervals, to BCBL-1 ce
he second and third applications. (C) LANA protein expression in cells treated
rotein required in the switching process from latency to lytic
eplication of KSHV (Sun et al., 1998). After RTA expression
s initiated, viral proinflammatory cytokines and transforming
enes are expressed, and lytic viral replication is activated (Sun
t al., 1998). LANA is crucial in maintaining KSHV latency.
hus, control of RTA and LANA protein expression may be an
ffective strategy to block KSHV replication.
KSHV-infected BCBL-1 cells are difficult to efficiently trans-
ect with common transfection reagents (Lukac et al., 1998,
999; Zhu et al., 2004). A recent report described the trans-
ection efficiency of BCBL-1 cells with Lipofectamine 2000
iposome (Invitrogen) to be approximately 10% (Zhu et al.,
004). PMO are non-charged compounds and, therefore, the
se of cationic lipids to deliver them cultured cells is ineffec-
ive (Ghosh and Iversen, 2000; Morcos, 2001). The conjugation
f arginine-rich peptides to PMO has proven to be an efficient
eans to deliver PMO into cultured cells. In this study, R5F2R4-
MO were tested for cellular uptake and persistence in BCBL-1
ells. The presence of P-PMO-F1 in treated BCBL-1 cells indi-
ated that R5F2R4 assisted in PMO uptake; as the corresponding
MO-F1 failed in the uptake assay. Flow cytometry analysis
onfirmed that P-PMO-F1 entered over 95% of the cells. Fur-
hermore, The P-PMO-F1 persisted for one week after a single
s
o
s
suantitative image analysis confirmed the LANA inhibition by LP2 or LP3 after
LP2 or LP3 is shown as a percentage relative to the mock-treatment control.
pplication. The uptake assays were conducted in the absence of
erum in the cell culture media. The R5F2R4-PMO used in this
tudy achieve relatively poor cellular uptake when applied in the
resence of serum. There have been recent reports, however, of
peptide-PMO conjugate (RXR)4XB-PMO, which is capable
f effective delivery into cells in the presence of serum (Deas
t al., 2005; Nelson et al., 2005). Delivery into relevant cells in
ivo has been a major challenge in the development of nucleic
cid-based therapeutic strategies.
To test the efficacy and specificity of P-PMO, we applied them
o KSHV-infected BCBL-1 and BC-1 cells in culture. Testing
he effect of P-PMO on target protein expression in these cells
as distinct relevance to a natural KSHV infection, as these cell
ines were derived from patients with PEL. The IFA and West-
rn blotting results demonstrate that RP1 P-PMO is effective
n blocking RTA protein expression in BCBL-1 cells in a dose-
esponsive and sequence-specific manner, as the control P-PMO
P1 and mRP1 had no effect. There remained faint RTA pro-
ein expression in BCBL-1 cells treated with 16M RP1, which
uggests that some cells achieved little or no uptake of P-PMO
r that an insufficient quantity of P-PMO made its way into the
ubcellular locations where RTA mRNA is translated. The above
peculation also provides potential explanation for why higher
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-PMO concentrations were required in cultured cells than in
he cell-free reporter assay to achieve an equivalent degree of
ranslation inhibition.
Our study showed that RP1 P-PMO suppressed RTA pro-
ein expression even when TPA induction was conducted at the
ame time as P-PMO treatment. The inhibition of RTA protein
xpression was less effective when RP1 was applied after TPA
nduction. This observation is consistent with a predicted mech-
nism of P-PMO action, that is, blocking the initiation of RNA
ranslation into protein (Summerton and Weller, 1997).
A cell viability assay indicated that RP1 had no detectable
ytotoxicity in the concentration range used in this study, sup-
orting the conclusion that suppression of RTA or other lytic
ene expression was due to the sequence-specific nature of P-
MO inhibition of RTA mRNA translation. Application of high
oncentrations of the P-PMO, however, may have some adverse
ffect on cells. We observed that the application of 16M RP1
or 4 h did result in approximately 5% cell mortality, and that
nclusion of BSA relieved this adverse effect.
RP1 P-PMO application to BCBL-1 cells resulted in reduced
xpression of a series of viral genes: vIL-6, vIRF-1, and ORF-
8.1A; these genes are typically expressed temporally down-
tream of RTA. KSHV viral DNA levels in intracellular and
ulture supernatant samples were also reduced. These results
emonstrate that KSHV lytic replication was abrogated in
CBL-1 cells after RTA P-PMO application. This pattern of
TA preeminence in the events of lytic progression is consistent
ith previous publications (Curreli et al., 2002; Zhu et al., 2004).
urreli et al. (2002) showed that methotrexate, a potent anti-
nflammatory agent and an inhibitor of cellular dihydrofolate
eductase, reduces the expression of ORF50/RTA and prevents
xpression of other lytic genes. The mechanism of this action is
ot known. Zhu et al. showed that a DNA-based external guid-
nce sequence (EGS) that targets RTA mRNA for RNase P-based
leavage was found to be an effective means to suppress KSHV
ytic replication in BCBL-1 cells, despite its limited transfection
fficiency (Zhu et al., 2004). The above studies strongly suggest
hat RTA is an appropriate target for antiviral therapy.
LP2 and LP3 P-PMO target the 5′UTR of a latent transcript
ncoding LANA, and were effective at inhibiting LANA protein
roduction, indicating that the target regions of those compounds
re essential for translation of the latent transcript. The efficacy
f LP3 suggests that it was able to inhibit the 5′UTR splic-
ng event of the 5.7 Kb latent transcript (Fig. 1), leading to a
eduction of 5.4 Kb transcript encoding LANA. Because the
atent transcript encoding ORF72/vCyclin and ORF71/vFLIP
s spliced from the same latent transcript as LANA (Dittmer et
l., 1998; Talbot et al., 1999), LP2 and LP3 P-PMO may have
he potential to inhibit the translation of these latent transcripts
s well.
LP1 was designed against the LANA translational start-site
egion, but had no detectable suppressive effect on LANA pro-
ein expression. We speculate that this target sequence region
f the latent LANA transcript may be inaccessible to P-PMO in
ells, as the same P-PMO was effective in an in vitro translation
eporter assay. RNA secondary structure analysis of the latent
ranscript using an mfold program (Zuker, 2003) revealed that
C
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omplex secondary structures likely exist in this translational
nitiation region (data not shown).
Current anti-herpesvirus drugs target the lytic rather than the
atent phase, and it has been reported that cidofovir and foscar-
et are the most efficient commercially available compounds
gainst KSHV (Kedes and Ganem, 1997; Medveczky et al.,
997; Sergerie and Boivin, 2003). Cidofovir and foscarnet have
o effect on expression of latent or early lytic genes (Curreli et
l., 2002), as these drugs are inhibitors of the viral DNA poly-
erase, and transcription of early lytic genes occurs before DNA
eplication in KSHV. LANA, RTA, and early lytic genes such
s vIL-6 (Aoki et al., 1999; Jones et al., 1999; Staskus et al.,
999) and vIRF-1 (Gao et al., 1997; Zimring et al., 1998) play
mportant roles in KSHV replication and pathogenesis. Blocking
xpression of these genes, and thereby that of down-stream genes
s well, could contribute to the treatment of KSHV-associated
alignancies. Antisense P-PMO compounds targeting RTA and
ANA may prove to be effective reagents to impede KSHV
eplication in vivo, and warrant further study.
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